Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’
Eli Lilly reports positive initial Phase 1 clinical data for its $2.3 billion acquisition of Ajax Therapeutics' myelofibrosis treatment.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Eli Lilly has released the first clinical findings regarding AJX-101, a type II JAK2 inhibitor developed by Ajax Therapeutics. Data from the Phase 1 study indicates that the drug, also referred to as AJ1-11095, reduced spleen size and alleviated symptoms in patients with previously treated myelofibrosis.
Coverage from outlets including BioSpace, Yahoo Finance, and Fierce Biotech highlights the drug's efficacy as a potential expansion of Lilly’s pipeline beyond obesity treatments. These reports emphasize that the findings are being presented at the 2026 EHA Annual Meeting, noting the clinical performance of the treatment among patients who had previously used type I JAK inhibitors.
Future developments hinge on subsequent clinical trial phases. Coverage does not yet specify a timeline for further testing or potential regulatory submissions for the therapy.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 154d ago.
Quick answers
What is the primary function of the drug AJX-101?
It is a first-in-class type II JAK2 inhibitor designed to treat myelofibrosis.
How much did Eli Lilly pay for the acquisition of Ajax?
Eli Lilly acquired Ajax for $2.3 billion.
Where are these study results being shared?
The data is being presented at the 2026 EHA Annual Meeting.
Coverage (8)
- Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacy BioSpace · 157d ago
- Eli Lilly JAK2 Data Highlights Pipeline Beyond Obesity And Valuation Upside Yahoo Finance · 157d ago
- Eli Lilly announces new data from Phase 1 AJX-101 study TipRanks · 157d ago
- Eli Lilly (LLY) Reports Promising Phase 1 Study Results for New Myelofibrosis Treatment GuruFocus · 157d ago
- Lilly trial drug cuts spleen size, symptoms in myelofibrosis Stock Titan · 157d ago
- AJ1-11095 Shows Spleen Responses and Symptom Improvement in Post–Type I JAK Inhibitor Myelofibrosis OncLive · 157d ago
- Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting investor.lilly.com · 157d ago
- Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’ Fierce Biotech · 157d ago
Topics
Related trends
Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
Seawolf Therapeutics launches with $100 million from Versant Ventures and Eli Lilly to develop non-viral gene therapies targeting obesity, muscle loss, and osteoporosis.
Makers of obesity drugs hit back at claims of negative side effects
Makers of obesity drugs defend their product safety amid mounting public scrutiny and reports of side effects.
Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
A former Eli Lilly sales representative has filed a retaliation lawsuit alleging she was fired for objecting to Mounjaro marketing.
Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
Eli Lilly's weight-loss pill Foundayo meets its main goal in a late-stage trial by easing sleep apnea.
Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials
Eli Lilly's experimental triple-hormone drug retatrutide cut knee osteoarthritis pain and produced average weight loss of roughly 25% in two Phase 3 trials involving more than 1,000 adults with obesity.
Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly
Eli Lilly has struck a deal allowing Hims & Hers Health to sell its obesity drugs Zepbound and Foundayo directly on its platform.